Telix Cleared to Commence Renal Cancer Imaging Study in Japan
Melbourne (Australia) and Kyoto (Japan) – 30 August 2019. Telix Pharmaceuticals Limited today announced the completion of a Clinical Trial Notification (CTN) review for a Phase I/II study for TLX250-C
MELBOURNE (Australia) and KYOTO (Japan) – Aug. 30, 2019
Telix Pharmaceuticals Limited today announced the completion of a Clinical Trial Notification (CTN) review for a Phase I/II study for TLX250-CDx (89Zr-girentuximab) in Japan. The Japanese Pharmaceutical and Medical Devices Agency (PMDA) has completed review of the proposed clinical trial and Telix is now permitted to proceed with the study. This study is the first of its kind in Japan.
To read the full media release click here.
Telix Pharmaceuticals and Pharmalogic Enter US Distribution Agreement for Prostate Cancer Imaging
Indianapolis IN and Boca Raton FL (U.S.A) – 15th May 2020. Telix Pharma (U.S.) announces it has entered into a commercial...
The Seneffe Manufacturing Site – Telix’s Next Big Move in Europe
1st May 2020 - Corporate Spotlight | Telix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe...
Seneffe Manufacturing Facility – Shareholder Walkthrough
Melbourne (Australia) 28 April 2020 - Telix Pharmaceuticals Limited provides a shareholder walkthrough of it's recently acquired Seneffe manufacturing facility
Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020
25th May 2020 - Clinical Spotlight | Telix Presents the IPAX-1 Study at the American Society of Clinical Oncology (ASCO)
Telix Pharmaceuticals Granted July Pre-IND Meeting with US FDA for Phase III ProstACT Study
Melbourne (Australia)– 14th May 2020. Telix has been granted a Type B pre-IND meeting with the FDA in relation to...